BidaskClub Upgrades Teva Pharmaceutical Industries Limited (TEVA) to Sell

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Wednesday.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald set a $31.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, June 22nd. Vetr cut Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 price target for the company. in a research report on Thursday, June 22nd. Citigroup Inc. cut Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $32.00 to $19.00 in a research report on Wednesday, August 16th. Maxim Group restated a “hold” rating and issued a $35.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Five investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $31.42.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 18.34 on Wednesday. Teva Pharmaceutical Industries Limited has a 52 week low of $15.22 and a 52 week high of $52.01. The company’s market cap is $18.64 billion. The firm has a 50-day moving average price of $19.41 and a 200 day moving average price of $28.68.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.25 EPS. Analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2017/09/15/bidaskclub-upgrades-teva-pharmaceutical-industries-limited-teva-to-sell.html.

Hedge funds have recently modified their holdings of the stock. San Francisco Sentry Investment Group CA bought a new stake in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter worth approximately $106,000. Bronfman E.L. Rothschild L.P. lifted its stake in shares of Teva Pharmaceutical Industries Limited by 7.8% during the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after acquiring an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC lifted its stake in shares of Teva Pharmaceutical Industries Limited by 74.7% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited during the 1st quarter worth approximately $123,000. Finally, Sterling Investment Advisors Ltd. lifted its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after acquiring an additional 100 shares during the last quarter. 56.87% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply